REAL-WORLD COSTS IN BIOLOGIC NAIVE PSORIATIC ARTHRITIS PATIENTS INITIATING APREMILAST OR BIOLOGICS IN A US HEALTHCARE CLAIMS DATABASE

被引：0
|
作者：
Kaplan, D. [1 ]
Ung, B. [2 ]
Udeze, C. [3 ]
Pelletier, C. [3 ]
Tian, M. [3 ]
机构：
[1] Adult & Pediat Dermatol, Overland Pk, KS USA
[2] Celgene Corp, Morris Plains, NJ USA
[3] Celgene Corp, Summit, NJ USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS15
引用
收藏
页码：S888 / S888
页数：1
相关论文
共 50 条
  • [21] Real-world trends in biologic, oral systemic, and phototherapy in US patients with psoriasis or psoriatic arthritis
    Singh, Partik
    Silverberg, Jonathan I.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (01) : 256 - 257
  • [22] EARLY REAL-WORLD EXPERIENCE OF TOFACITINIB FOR PSORIATIC ARTHRITIS: DATA FROM A UNITED STATES HEALTHCARE CLAIMS DATABASE
    Mease, P. J.
    Young, P.
    Gruben, D. C.
    Fallon, L.
    Germino, R.
    Kavanaugh, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1286 - 1287
  • [23] Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database
    Mease, Philip
    Young, Pamela
    Gruben, David
    Fallon, Lara
    Germino, Rebecca
    Kavanaugh, Arthur
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [24] Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database
    Mease, Philip J.
    Young, Pamela
    Gruben, David
    Fallon, Lara
    Germino, Rebecca
    Kavanaugh, Arthur
    ADVANCES IN THERAPY, 2022, 39 (06) : 2932 - 2945
  • [25] Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database
    Philip J. Mease
    Pamela Young
    David Gruben
    Lara Fallon
    Rebecca Germino
    Arthur Kavanaugh
    Advances in Therapy, 2022, 39 : 2932 - 2945
  • [26] PERSISTENCE AND ADHERENCE AT 12 MONTHS WITH SUBCUTANEOUSLY ADMINISTERED BIOLOGICS AMONG BIOLOGIC-NAIVE AND-EXPERIENCED PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSES FROM A US CLAIMS DATABASE
    Oelke, K. R.
    Chambenoit, O.
    Majjhoo, A. Q.
    Gray, S.
    Higgins, K.
    Hur, P.
    VALUE IN HEALTH, 2018, 21 : S201 - S201
  • [27] Comparison of the real-world costs associated with different treatment patterns in adults initiating apremilast or biologics for the treatment of psoriasis
    Feldman, Steven
    Bonafede, Machaon
    Pelletier, Corey
    Mehta, Rina
    Wilson, Kathleen
    Smith, David
    Brouillette, Matthew
    Li, Qing
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB84 - AB84
  • [28] Biologic Initiation Rate in Systemic-Naive Psoriatic Arthritis Patients Starting Treatment with Apremilast vs Methotrexate: 1-Year Retrospective Analysis of a US Claims Database
    Husni, M. Elaine
    Chang, Eunice
    Broder, Michael S.
    Paydar, Caleb
    Bognar, Katalin
    Desai, Pooja
    Klyachkin, Yuri
    Khilfeh, Ibrahim
    OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS, 2022, 14 : 123 - 132
  • [29] Characteristics and Treatment Patterns Among Patients with Psoriatic Arthritis Initiating Subcutaneously Administered Biologics: Descriptive Analyses from a US Claims Database
    Oelke, Kurt R.
    Garg, Rahul
    Hur, Peter
    Chambenoit, Olivier
    Majjhoo, Amar Q.
    Gray, Stephani
    Higgins, Kate
    Palmer, Jacqueline B.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [30] SWITCH PATTERNS AND TOTAL COSTS IN BIOLOGIC-NAIVE PATIENTS INITIATING APREMILAST OR A BIOLOGIC FOR THE TREATMENT OF PSORIASIS
    Wu, J.
    Pelletier, C.
    Ung, B.
    Tian, M.
    Ni, Q.
    Curtis, J. R.
    VALUE IN HEALTH, 2018, 21 : S426 - S426
12345